Background. In this study the effects of 24 weeks losartan and ramipril treatment,
both alone and in combination, on blood pressure and left ventricular mass (LVM) and function,
have been evaluated in hypertensives.
Methods. 57 hypertensives with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, 3 arm, double dummy, independent trial was used. All patients were randomly allocated to 3 treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/daily), and combined (losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM, LVM/h2.7 and other echocardiographic measurements, BUN, creatinine and clearance and potassium were determined after run in and 24 weeks.
Results. All groups were comparable for gender, age, BMI, BP and LVM. The prevalence of baseline left ventricular hypertrophy (LVH) was not significantly different among 3 groups. At the end of treatment, a significant (p<0.05) reduction in SBP, DBP, MBP, LVM and LVM/h2.7 were observed in all groups. The absolute and percent reduction in LVM/h2.7 were significantly higher in combined than losartan or ramipril groups and also in hypertensives with LVH. No significant change in absolute and percent reduction of SBP, DBP and MBP were found. Conclusions. These data indicate an additional cardioprotective effect of dual blockade of RAS in hypertensive patients with and without left ventricular hypertrophy. (Heart International 2006; 2: 39-48)
Ace-inhibitors, Angiotensin II receptor blockers, Left ventricular geometry and function
Rosario Scaglione, MD, Associate Professor of Medical Therapy, Via Lombardia, 9, 90144 Palermo – Italy, email@example.com
Share this Article
Related Content In Hypertension
Atrial Fibrillation and Dementia
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):10-6 DOI: https://doi.org/10.17925/EJAE.2020.6.1.10
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF during their lifetime.2,3 Irrespective of age, AF incidence also increases with diabetes […]
Renal Denervation in High-risk Patients with Hypertension
Heart International. 2019;13(2):12-6
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular disease and end-stage renal disease.2 Renal denervation (RD) is an emerging treatment modality which allows […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!